Molecules that target beta-amyloid.

Area of Science:

• Neuroscience and Molecular Biology
• Biochemistry of Protein Aggregation

Background:

• Alzheimer's disease and related amyloidogenic disorders are characterized by beta-amyloid peptide aggregation.
• Understanding the molecular mechanisms of beta-amyloid aggregation is critical for developing effective interventions.

Purpose of the Study:

• To review molecules that interact with oligomeric or fibrillar forms of the beta-amyloid peptide.
• To explore natural proteins, peptides, peptidomimetics, and small molecules that inhibit beta-amyloid aggregation.
• To discuss recent advancements in selecting targeted anti-amyloid molecules from various libraries.

Main Methods:

• Literature review of studies investigating molecular interactions with beta-amyloid aggregates.
• Analysis of natural and synthetic molecules (proteins, peptides, peptidomimetics, small molecules) that interfere with aggregation.
• Examination of selection strategies for molecules targeting beta-amyloid from antibody, protein, and peptide libraries.

Main Results:

• Identification of diverse molecular classes, including natural proteins, peptides, peptidomimetics, and small molecules, that interact with beta-amyloid.
• Demonstration that these molecules can interfere with beta-amyloid aggregation pathways.
• Highlighting the utility of library-based selection methods for discovering novel anti-amyloid agents.

Conclusions:

• The reviewed molecules provide valuable tools for deciphering the beta-amyloid aggregation pathway.
• These agents can potentially stabilize oligomeric intermediates relevant to Alzheimer's disease pathophysiology.
• The anti-amyloid molecular toolbox offers a promising avenue for designing new diagnostic and therapeutic reagents.